The ability to develop resistance is the most important biological characteristic of the acid-fast bacillus and the one which most influences the approach to chemotherapy. Clinical and experimental data support that a three-drug regimen, administered daily in the initial period of treatment will achieve 100% success, . Of these three drugs, at least two must be bactericidal, e.g., isoniazid, streptomycin, rifampicin or pyrazinamide. "Intensive Phase Therapy", lasting from three to six weeks, will be followed by a two drug regimen to complete a total of 12 weeks. The possibility of short-course therapy is being explored through extensive research. On the basis of knowledge obtained so far, chemotharapy for 9 months seems to be fully effective and its value well documented.